Published in J Am Soc Nephrol on December 01, 2004
Development of antihuman IgG antibodies and hematologic deficits but not clinical abnormalities in C57BL/6 mice after repeated administration of human intravenous immunoglobulin. Comp Med (2012) 1.61
The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient mice. Kidney Int (2012) 1.52
Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol (2010) 1.16
Are low inflammatory reactions involved in exudative age-related macular degeneration? Morphological and immunhistochemical analysis of AMD associated with basal deposits. Graefes Arch Clin Exp Ophthalmol (2008) 1.13
Serum cystatin C level, kidney disease markers, and incidence of age-related macular degeneration: the Beaver Dam Eye Study. Arch Ophthalmol (2009) 1.05
MPGN II--genetically determined by defective complement regulation? Pediatr Nephrol (2006) 1.02
Borrelia burgdorferi binding of host complement regulator factor H is not required for efficient mammalian infection. Infect Immun (2007) 0.95
Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation. FASEB J (2009) 0.93
Curcumin alleviates immune-complex-mediated glomerulonephritis in factor-H-deficient mice. Immunology (2013) 0.84
Abrogation of immune complex glomerulonephritis by native carboxypeptidase and pharmacological antagonism of the C5a receptor. Cell Mol Immunol (2015) 0.83
Complement regulation in renal disease models. Semin Nephrol (2013) 0.80
CD11b is protective in complement-mediated immune complex glomerulonephritis. Kidney Int (2015) 0.78
Mesangial cell complement receptor 1-related protein y limits complement-dependent neutrophil accumulation in immune complex glomerulonephritis. Immunology (2009) 0.77
Complement factor H gene associations with end-stage kidney disease in African Americans. Nephrol Dial Transplant (2014) 0.77
Novel factor H mutation associated with familial membranoproliferative glomerulonephritis type I. Pediatr Nephrol (2015) 0.75
VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med (2008) 9.87
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet (2010) 3.74
Pathologic classification of diabetic nephropathy. J Am Soc Nephrol (2010) 3.61
C3 glomerulopathy: a new classification. Nat Rev Nephrol (2010) 3.17
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
C3 glomerulopathy: consensus report. Kidney Int (2013) 2.85
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J (2008) 2.75
Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J Neuropathol Exp Neurol (2005) 2.58
miR-17-92 cluster accelerates adipocyte differentiation by negatively regulating tumor-suppressor Rb2/p130. Proc Natl Acad Sci U S A (2008) 2.42
Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. Am J Transplant (2004) 2.22
Detection of glomerular complement C3 fragments by magnetic resonance imaging in murine lupus nephritis. Kidney Int (2011) 2.20
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Pros and cons for C4d as a biomarker. Kidney Int (2012) 2.03
Acute renal failure in endotoxemia is caused by TNF acting directly on TNF receptor-1 in kidney. J Immunol (2002) 1.96
Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest (2008) 1.94
DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol (2012) 1.93
The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol (2010) 1.88
C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol (2002) 1.88
Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J Immunol (2004) 1.82
Complement in human diseases: Lessons from complement deficiencies. Mol Immunol (2009) 1.73
ABO incompatible renal transplantation: a paradigm ready for broad implementation. Transplantation (2009) 1.71
Administration of a soluble recombinant complement C3 inhibitor protects against renal disease in MRL/lpr mice. J Am Soc Nephrol (2003) 1.68
Immunotactoid keratopathy: a clinicopathologic case report and a review of reports of corneal involvement in systemic paraproteinemias. Surv Ophthalmol (2004) 1.67
Dimerization of complement factor H-related proteins modulates complement activation in vivo. Proc Natl Acad Sci U S A (2013) 1.63
Complement factor H deficiency in aged mice causes retinal abnormalities and visual dysfunction. Proc Natl Acad Sci U S A (2007) 1.62
Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int (2009) 1.56
In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol (2010) 1.54
The C5a receptor has a key role in immune complex glomerulonephritis in complement factor H-deficient mice. Kidney Int (2012) 1.52
Experimental membranous nephropathy redux. Am J Physiol Renal Physiol (2005) 1.52
A hybrid CFHR3-1 gene causes familial C3 glomerulopathy. J Am Soc Nephrol (2012) 1.52
C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation. J Clin Invest (2013) 1.52
Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics? Kidney Int (2005) 1.51
Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. J Hum Genet (2012) 1.46
Injury in renal ischemia-reperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol Renal Physiol (2002) 1.45
C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol (2007) 1.45
Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. Clin Cancer Res (2005) 1.44
Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation (2002) 1.43
Renal FcRn reclaims albumin but facilitates elimination of IgG. J Am Soc Nephrol (2009) 1.40
Pathogenic natural antibodies recognizing annexin IV are required to develop intestinal ischemia-reperfusion injury. J Immunol (2009) 1.38
TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1. Neurochem Int (2007) 1.34
Dense deposit disease. Mol Immunol (2011) 1.31
B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci U S A (2010) 1.26
Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. Kidney Int (2010) 1.25
Acute renal failure in endotoxemia is dependent on caspase activation. J Am Soc Nephrol (2004) 1.22
Recent insights into C3 glomerulopathy. Nephrol Dial Transplant (2013) 1.21
C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol (2013) 1.19
The follicular dendritic cell restricted epitope, FDC-M2, is complement C4; localization of immune complexes in mouse tissues. Eur J Immunol (2002) 1.19
Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol (2010) 1.16
C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol (2005) 1.16
Negative regulation of CD40-mediated B cell responses by E3 ubiquitin ligase Casitas-B-lineage lymphoma protein-B. J Immunol (2007) 1.16
Mouse podocyte complement factor H: the functional analog to human complement receptor 1. J Am Soc Nephrol (2007) 1.16
Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation (2010) 1.15
Sarcoidosis: the nephrologist's perspective. Am J Kidney Dis (2006) 1.14
Design and evaluation of meningococcal vaccines through structure-based modification of host and pathogen molecules. PLoS Pathog (2012) 1.10
Specific and durable elimination of antibody to donor HLA antigens in renal-transplant patients. Transplantation (2003) 1.10
Factor H facilitates the clearance of GBM bound iC3b by controlling C3 activation in fluid phase. Mol Immunol (2009) 1.09
Antibody-mediated rejection in renal allografts: lessons from pathology. Clin J Am Soc Nephrol (2006) 1.09
Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol (2005) 1.08
P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol (2009) 1.08
The simple design of complement factor H: Looks can be deceiving. Mol Immunol (2006) 1.07
Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol (2006) 1.07
C5a alters blood-brain barrier integrity in experimental lupus. FASEB J (2010) 1.06
Absence of functional alternative complement pathway alleviates lupus cerebritis. Eur J Immunol (2007) 1.06
Chronic kidney disease induced in mice by reversible unilateral ureteral obstruction is dependent on genetic background. Am J Physiol Renal Physiol (2010) 1.06
The role of the complement cascade in endotoxin-induced septic encephalopathy. Lab Invest (2007) 1.05
Unrestricted C3 activation occurs in Crry-deficient kidneys and rapidly leads to chronic renal failure. J Am Soc Nephrol (2007) 1.05
Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant (2004) 1.05
Cocaine use and hypertensive renal changes in HIV-infected individuals. Clin J Am Soc Nephrol (2007) 1.03
Acute presentation and persistent glomerulonephritis following streptococcal infection in a patient with heterozygous complement factor H-related protein 5 deficiency. Am J Kidney Dis (2012) 1.03
Phagocytosis is the main CR3-mediated function affected by the lupus-associated variant of CD11b in human myeloid cells. PLoS One (2013) 1.01
Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9. J Immunol (2005) 1.01
Transgenic expression of a soluble complement inhibitor protects against renal disease and promotes survival in MRL/lpr mice. J Immunol (2002) 1.00
Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int (2011) 1.00
Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J Am Soc Nephrol (2003) 0.99
Complement-dependent apoptosis and inflammatory gene changes in murine lupus cerebritis. J Immunol (2005) 0.99
Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy. Int J Surg Pathol (2005) 0.99
Dense deposit disease and C3 glomerulopathy. Semin Nephrol (2013) 0.98
Complement in lupus nephritis: the good, the bad, and the unknown. Semin Nephrol (2007) 0.97
Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis. Biochim Biophys Acta (2003) 0.97
CTL-promoting effects of CD40 stimulation outweigh B cell-stimulatory effects resulting in B cell elimination and disease improvement in a murine model of lupus. J Immunol (2008) 0.97
Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice. Am J Pathol (2009) 0.96
Focal and segmental glomerulosclerosis induced in mice lacking decay-accelerating factor in T cells. J Clin Invest (2009) 0.96
Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Mol Immunol (2008) 0.96
Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates. Infect Immun (2013) 0.95